Format

Send to

Choose Destination
Br J Cancer. 2011 Feb 1;104(3):392-8. doi: 10.1038/sj.bjc.6606030. Epub 2010 Dec 7.

Targeting BRAF for patients with melanoma.

Author information

1
Sarah Cannon Research UK, 93 Harley Street, London W1G 6AD, UK. tobias.arkenau@sarahcannonresearch.co.uk

Abstract

The prognosis of patients with metastatic melanoma is poor and not influenced by systemic therapy with cytotoxic drugs. New targeted agents directed against the RAS-RAF-MEK-ERK pathway show promising activity in early clinical development and particular interest is focused on selective inhibitors of mutant BRAF, which is present in one half of the cases of metastatic melanoma. The majority of patients on early trials of these drugs develop secondary resistance and subsequent disease progression and it is, therefore, critical to understand the underlying escape mechanisms leading to resistance.

PMID:
21139585
PMCID:
PMC3049553
DOI:
10.1038/sj.bjc.6606030
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center